



BUILD VENTURES ADVANCE HEALTH

Biotech

Partnership opportunities




NLC
THE EUROPEAN HEALTHTECH
VENTURE BUILDER




A STRUCTURED PROCESS AND A STRONG NETWORK ENABLES NLC TO BUILD AND SUPPORT VENTURES

OUR PROCESS



OUR NETWORK



NLC PROVIDES THE SUPPORT ECOSYSTEM



Research & Development

- Gap analysis
- Preclinical and clinical R&D plan
- Project management



Venture Support

- Kickstarter programme
- Service providers
- Clinical trial assistance



Venture Teaming

- CEO recruitment
- Team development



Venture Finance

- Financial strategy
- (Non)-dilutive funding
- Captive funds




Venture protection

- Legal support
- Patent and trademark support
- Quality and regulatory support



THE TWO MODELS OF BIOTECH VENTURE BUILDING



WE HELP SECURE CAPITAL FOR OUR VENTURES



OUR NETWORK

- Non-dilutive & dilutive funding access (ERC, EIC, EuroStars)
- Europe & US
- Biopharma & Biotech
- CROs/CDMOs/service providers & consultants
- Venture capital/incubators/accelerators
- Patient associations and foundations




OUR FUNDS

- Stepping stone
- Momentum
- **Health Impact Fund: €100M Series A growth fund** (supporting Venture Creation model)
- **Biotech fund (from 2024) €50M pre-/seed fund** (supporting Pre-venture model)



NLC'S PLATFORM SUPPORTS COLLABORATION



WHAT WE CAN DO TOGETHER (Corporates, pharma, Biotechs)



Externalise innovation

- Joint ventures
- Spin out de-prioritised assets
- Outlicense IP
- Co-development



Exit partners

- Acquisition of preclinical programmes
- Acquisition of ventures
- Build-to-buy model



Investments

- Co-investment in projects
- Investments in ventures
- Investments in NLC funds to get a front-row seat



Selection partner

- Strategic project selection
- First hand exposure to pipeline
- Right of first negotiation



Advisory members

- Advisory board members
- Expert panel participation
- Investment committees



WHAT WE CAN DO TOGETHER (Investors incl VCs)



Venture portfolio

- Selection from a large portfolio
- Updates on new venture creation



Co-development

- Co-creation
- Co-funding and co-development



Investments

- Co-investments in early stage projects
- Investments in ventures
- Investments in NLC funds (fund-in-fund)



Project selection

- Selection of strategic projects
- Access to early stage innovative projects
- Due diligence



WHAT WE CAN DO TOGETHER (Service providers)



Strategic partnership

- Access to large venture portfolio
- Project selection
- Reward sharing



Risk and value sharing

- Success/milestone based
- Equity for service
- Long term commitment



Fee for service

- Fixed cost
- FTE-based
- Discounted rates



Externalise innovation

- Spin out early stage assets
- Build joint ventures



WHAT WE CAN DO TOGETHER (VB/incubator/accelerator)



Strategic partnership

- Access to large pre-selected asset pool
- Established global network
- Streamlined venture building



Risk and value sharing

- Joint ventures
- Co-development




Collaboration

- Deal-flow sharing
- Advisory board
- Investment committee



OUR TRACK RECORD

We combine years of experience in venture creation, fundraising and the right expertise making us the powerhouse in translating breakthrough science into thriving biotech companies.



THE TEAM

Project Selection & Business Development



Kathrin Ballesteros, PhD
Venture Partner



Ankita Das, MSc
Venture Developer



Gabor Heltovcics, MBA
Venture Partner



Lydia Kalafateli, PhD, MBA
Venture Developer



Rita Mendes, PhD
Venture Developer



Simon Loiodice, PhD
Advisor



R&D



Ljudmila Katchan, PhD
Lead R&D



Hanneke van der Kleij, PhD
Lead R&D




Partners



A SELECTION OF BIOTECH VENTURES IN PORTFOLIO

			
	Phase I ready	Phase I ready	Pre-IND
Therapeutic area	Orthopedic injuries & osteoarthritis	Chronic & burn wounds	Mental disorders
Modality	Autologous cell therapy	Novel enzymatic debrider	Biologic/neuroimmunological target
Current status	Recently raised a 4M Series A	Currently fundraising: Series A	Currently fundraising: Seed
Origin			





NLC

THE EUROPEAN HEALTHTECH
VENTURE BUILDER

BUILD VENTURES ADVANCE HEALTH

Lydia Kalafateli

✉ lydia.kalafateli@nlc.health

☎ +31649713284



A SELECTION OF OUR BIOTECH VENTURES IN PORTFOLIO

			
	Phase I ready	Phase I ready	Pre-IND
Therapeutic area	Orthopedic injuries & osteoarthritis	Chronic & burn wounds	Mental disorders
Modality	Autologous cell therapy	Novel enzymatic debrider	Biologic/neuroimmunological target
Current status	Recently raised a 4M Series A	Currently fundraising: Series A	Currently fundraising: Seed
Origin			

(SPIN OUT) MODELS DEPEND ON STRATEGIC INTEREST AND PREFERRED LEVEL OF CONTROL

